Slide 1: Cyclopharm Limited Annual General Meeting
For personal use only Cyclopharm Limited Annual General Meeting 26 May 2011
Slide 2: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 3: Agenda
Agenda For personal use only Chairman’ss Address Chairman Managing g g Director’s Review Question Time Business Close 3
Slide 4: Chairman's Address
For personal use only Chairman’ss Address Chairman Vanda Gould 4
Slide 5: Managing Director's Review
For personal use only Managing Director’s Director s Review James McBrayer 5
Slide 6: Cyclopharm business
Cyclopharm business Three business units For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals p Diagnostic g Imaging g g Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharma
Slide 7: Highlights - Financial Year 2010
Highlights ‐ Financial Year 2010 For personal use only A Year of Transformation Technegas business strong and consistent Cyclotron facility receives TGA license Start‐up St t C l t Cyclotron f ilit generating facility ti revenues Start‐up Diagnostic Imaging joint venture generating revenues
Slide 8: Segmental Overview
For personal use only Segmental Overview 8
Slide 9: Technegas: Components of Technegas
Technegas For personal use only Components of Technegas There are four components required for a Technegas procedure: d 1. Generator 1. Technegas Generator 2 A single 2. i l use P Patient ti t Ad Administration i i t ti 2. PAS Set (PAS) 3. A single g use p patient crucible 4. Technetium 99m All non-
Slide 10: Technegas: Global footprint
Technegas Global footprint For personal use only • Technegas is sold in 55 countries across the world • Over 2,500,000 patient studies since 1986 • 162,800 patient studies conducted in 2010 N th North Asia i • 1,163 Technegas generators sold globally America, Pacific, 17% 23% Europe • Patents in 36
Slide 11: Molecular Imaging - Positron Emission Tomography (PET)
Molecular Imaging ‐ Positron Emission Tomography h ((PET)) For personal use only PET is the future of Nuclear Medicine. Positron Emission Tomography allows physicians to differentiate between healthy and active diseased tissue. PET is primarily used in the detection of cancer but . rapid growth in o
Slide 12: Macquarie University Hospital
Macquarie University Hospital For personal use only • 183 bed university hospital • 12 operating p g theatres • Specialising in Oncology and Neurology • Home of the Australian School of Advanced Medicine • Adjacent specialty clinic containing 18 specialist suites • Home of a Gamma knife
Slide 13: Diagnostic Imaging
Diagnostic Imaging For personal use only PET • Joint venture with Alfred Health X‐Ray X Ray Solutions CT • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform MRI • Inpatient pat e t aand d outpat outpatient e t se services ces Ultra‐ sound • Foundation for regi
Slide 14: 2010 Financials
For personal use only 2010 Financials 14
Slide 15: Profit & Loss
Profit & Loss For personal use only Profitable Profitable while investing for the future 2010 2009 $ $ • Overall revenue down CONTINUING OPERATIONS 14.7% but volumes Sales revenue 9 464 605 9,464,605 11 098 579 11,098,579 remaining consistent Finance revenue 68,972 93,186 Other revenue - 2,403,090
Slide 16: Profit & Loss: Adjusted
Profit & Loss For personal use only Adjusted Adjusted Net Profit After Tax consistent Full Year ending 31 December 2008 2009 2010 % Change Sales Revenue #039;000 10,888 11,099 9,465 (14.7%) Net Profit Before Tax #039;000 1,896 2,568 808 (68.5%) Adjusted Net Profit Before Tax* #039;000 1,896 2,044 1,983 (3.0
Slide 17: Sales revenue - Segmental Review
Sales revenue ‐ Segmental Review For personal use only Sales impacted by Molybdenum Crisis & Foreign Exchange Patient Administration Sets (PAS) • PAS revenue down 19% to $7.36 m • PAS volumes consistent Technegas Generators • Generator G t volumes l up 11% • Generator revenue down 3% • Other h reven
Slide 18: Sales revenue: Half year comparison
Sales revenue Half lf year comparison For personal use only Historical Trend – strong second half results continues 18
Slide 19: Balance Sheet
Balance Sheet For personal use only Consistent Net Asset Position • PET Facilityy at MUH Balance Sheet Summary 2010 2009 $ $ reclassified as Property Total Current Assets 8,409,488 12,169,793 Plant & Equipment since Total Non-current Assets 13,732,411 7,474,618 commissioning Total Assets 22,141,89
Slide 20: Operating Cash flow
Operating Cash flow For personal use only Closing cash of $1.5m • Prior P i year cash h ffrom operating i 2010 2009 activities included the $ $ Operating activities (90,960) 3,691,033 US$1.8m $ settlement with Investing activities (6,218,108) (3,096,865) Clinquest Inc (offset by $0.8m Financing ac
Slide 21: Business Outlook 2011
For personal use only Business Outlook 2011 21
Slide 22: Business Outlook: Technegas
Business Outlook Technegas h For personal use only New Drug Application (NDA) • Invetigational New Drug Application to be submitted Q3 2011 • Clinical trial commencement targeted Q3 2011 New Indications for Technegas • Collaborations underway with researchers and clinicians • COPD and Lung Cancer ta
Slide 23: Business Outlook: PET Radiopharmaceuticals
Business Outlook PET Radiopharmaceuticals d h l For personal use only Macquarie University Hospital (MUH) • Continue to expand p our FDG customer base in NSW • Focus on new product development • Develop l clinical li i l research h opportunities ii Expansion Opportunities • Evaluate expansion opport
Slide 24: Business Outlook: Diagnostic Imaging
Business Outlook Diagnostic Imaging For personal use only Macquarie q Medical Imaging g g • Continue to support minority shareholding • Implement breast clinic services in collaboration with the University • Expand Cancer Care Clinic b l and visibility d service offering ff • Leverage growth in PET
Slide 25: Conclusion
For personal use only Conclusion 25
Slide 26: Cyclopharm business
Cyclopharm business For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals p Diagnostic g Imaging g g Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to produce PET s
Slide 27: Question Time & Business
For personal use only Question Time & Business 27
Slide 28: Proxy Summary
Proxy Summary For personal use only R Resolution l ti B i Business F * For* A i t Against Ab t i Abstain Proxy’s P ’ discretion 1 Remuneration Report 82,395,487 50,293 27,286 15,829 2 Re-election of Mr David 82,463,971 9,095 0 15,829 Heaney 3 Share Buy-back 82,460,780 12,286 0 15,829 4 Long Term Inc
Slide 29: Attachments
For personal use only Attachments 29